Mylan Labs CEO on Price Controls, Biogenerics, and D.C.’s Recent Power Shift

Interview with Robert Coury, Head of Mylan Laboratories

BLOOM (BLOOM), National

Wed 8 Nov 2006 01:44 PM EDT

Coury discusses what to expect from Congress re: generics and namebrand drugs. Interesting comments on price controls, reimportation and biogenerics